We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
-3.86%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$103M
AUM Growth
-$21.1M
Cap. Flow
-$8.51M
Cap. Flow %
-8.28%
Top 10 Hldgs %
58.07%
Holding
75
New
23
Increased
18
Reduced
24
Closed
9

Top Buys

Rank Stock Value
1
SRZN icon
Surrozen
SRZN
+$1.73M
2
ANIP icon
ANI Pharmaceuticals
ANIP
+$1.65M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$1.6M
4
EDSA icon
Edesa Biotech
EDSA
+$1.48M
5
OPTN
OptiNose
OPTN
+$1.26M

Top Sells

Rank Stock Value
1
ADMA icon
ADMA Biologics
ADMA
+$7.45M
2
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$2.87M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$2.68M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$2.3M
5
EOLS icon
Evolus
EOLS
+$1.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PROF
26
Profound Medical
PROF
$268M
$814K 0.79%
139,942
-60,058
-30% -$415K
AYTU icon
27
AYTU BioPharma
AYTU
$23.9M
$795K 0.77%
463,721
+56,172
+14% +$81.7K
GERN icon
28
Geron
GERN
$828M
$795K 0.77%
+500,000
New +$1.22M
THRD
29
DELISTED
Third Harmonic Bio
THRD
$738K 0.72%
+212,783
New +$1.03M
PMVP icon
30
PMV Pharmaceuticals
PMVP
$59.2M
$687K 0.67%
630,183
+94,378
+18% +$128K
GRCE
31
Grace Therapeutics
GRCE
$33.8M
$666K 0.65%
+294,550
New +$928K
ITOS
32
DELISTED
iTeos Therapeutics
ITOS
$657K 0.64%
110,000
– –
CALC icon
33
CalciMedica
CALC
$15.8M
$615K 0.6%
367,371
-101,422
-22% -$253K
COLL icon
34
Collegium Pharmaceutical
COLL
$1.15B
$615K 0.6%
+20,607
New +$630K
KPRX icon
35
Kiora Pharmaceuticals
KPRX
$11.3M
$604K 0.59%
200,647
-323
-0.2% -$1.12K
YMAB
36
DELISTED
Y-mAbs Therapeutics
YMAB
$581K 0.57%
+131,160
New +$761K
XERS icon
37
Xeris Biopharma Holdings
XERS
$1.39B
$561K 0.55%
102,265
-80,052
-44% -$323K
CHRS icon
38
Coherus Oncology
CHRS
$217M
$501K 0.49%
620,588
+370,588
+148% +$427K
KZR
39
DELISTED
Kezar Life Sciences
KZR
$488K 0.47%
100,000
-10,000
-9% -$60.7K
SLRN
40
DELISTED
ACELYRIN
SLRN
$414K 0.4%
167,580
+34,710
+26% +$82.5K
NBP
41
NovaBridge Biosciences American Depositary Shares
NBP
$185M
$398K 0.39%
+483,647
New +$459K
SEPN
42
Septerna Inc
SEPN
$1.55B
$394K 0.38%
+68,084
New +$777K
HLVX
43
DELISTED
HilleVax
HLVX
$346K 0.34%
238,950
+106,603
+81% +$197K
XGN icon
44
Exagen
XGN
$109M
$344K 0.33%
95,747
-155,302
-62% -$586K
RNXT icon
45
RenovoRx
RNXT
$43.2M
$275K 0.27%
+278,188
New +$324K
KALV
46
DELISTED
KalVista Pharmaceuticals
KALV
$249K 0.24%
+21,550
New +$220K
ACET icon
47
Adicet Bio
ACET
$85.2M
$204K 0.2%
31,767
-11,983
-27% -$171K
CRGX
48
DELISTED
CARGO Therapeutics
CRGX
$204K 0.2%
+50,000
New +$335K
MIST icon
49
Milestone Pharmaceuticals
MIST
$138M
$200K 0.19%
250,000
-250,000
-50% -$497K
BIOA
50
BioAge Labs
BIOA
$402M
$188K 0.18%
+50,000
New +$231K
1
2
3

Similar funds

ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Stonepine Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Stonepine Capital Management held 75 positions worth $103M, down 17% from $124M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Stonepine Capital Management withdrew a net $8.51M in Q1 2025, closing 9 positions and reducing 24 holdings. Its most notable exit was Ironwood Pharmaceuticals, an estimated $2.87M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Stonepine Capital Management opened a new position in Edesa Biotech worth $1.68M.

  • Stonepine Capital Management's largest Q1 2025 buy was Edesa Biotech: 687,500 shares worth $1.68M.
  • Stonepine Capital Management added most to Surrozen in Q1 2025, an estimated $1.73M increase.
  • Stonepine Capital Management's biggest Q1 2025 reduction was ADMA Biologics, cutting an estimated $7.45M.
  • Stonepine Capital Management fully exited Ironwood Pharmaceuticals in Q1 2025, selling an estimated $2.87M.
  • Stonepine Capital Management's ten largest holdings make up 58% of its $103M portfolio in Q1 2025.
  • Stonepine Capital Management opened 23 new positions and closed 9 in Q1 2025.
  • Stonepine Capital Management's portfolio value fell 17% quarter-over-quarter to $103M.

Based on Stonepine Capital Management's 13F filing for Q1 2025, filed 14 May 2025.